OBP-801 is a histone deacetylase (HDAC) inhibitor, having specific and strong activity on HDAC, which is expected to show anticancer effect by promoting an expression of tumor suppressor genes in cancer cell and inducing apoptotic and autophagic cell death.
The results of pre-clinical studies on OBP-801 indicated the most potent HDAC inhibitory activity as compared to other HDAC inhibitors including and Zolinza® and Istodax®, and its efficacy on a wide range of cancers is expected.
Furthermore, Oncolys has been exploring the potential ophthalmic use of OBP-801 in collaboration with Kyoto Prefectural University of Medicine.


Target indication

Lung cancer, lymphoma, kidney cancer, and glaucoma

Current status

We concluded a worldwide exclusive license agreement with Astellas Pharma Inc. on October 2009 to develop, manufacture and commercialize OBP-801.
After completion of preclinical and CMC works, we filed an IND to the US FDA in 2014 and have been conducting phase 1 clinical study for solid tumor.
For the ophthalmic use, we initiated to explore the possibility of using OBP-801 as an alternate drug of mitomycin C in glaucoma operation in collaboration with Kyoto Prefectural University of Medicine.